NCT00478205View on ClinicalTrials.gov

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

1,467

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

June 30, 2009

Conditions
Alzheimer's Disease
Interventions
DRUG

Aricept (donepezil SR 23 mg)

"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation."

DRUG

Aricept (donepezil IR 10 mg)

"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation."

Trial Locations (1)

28601

MedTrials, Inc., Hickory

All Listed Sponsors
collaborator

Eisai Limited

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT00478205 - Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease | Biotech Hunter | Biotech Hunter